ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, David C.S. Huang et al.|Nature Medicine|2013Cited by 3k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Darren C. Phillips et al.|Science Translational Medicine|2015Cited by 541
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> ActivityZhi‐Fu Tao, Andrew J. Souers, Lisa Hasvold et al.|ACS Medicinal Chemistry Letters|2014Cited by 331
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208Andrew J. Souers, Steven W. Elmore, Erwin R. Boghaert et al.|Unknown|2013Cited by 182
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C. Phillips, Edward B. Reilly, Erwin R. Boghaert et al.|Molecular Cancer Therapeutics|2018Cited by 52